screening tool
Recently Published Documents


TOTAL DOCUMENTS

6299
(FIVE YEARS 3048)

H-INDEX

91
(FIVE YEARS 22)

2022 ◽  
Vol 43 (2) ◽  
pp. 103327
Author(s):  
Jonathan Reid ◽  
Preet Parmar ◽  
Tyler Lund ◽  
Daniel K. Aalto ◽  
Caroline C. Jeffery

2022 ◽  
Author(s):  
Padmapani Padeniya ◽  
Dileepa S Ediriweera ◽  
Arjuna De Silva ◽  
Madunil Niriella ◽  
Anuja Premawardhena

Abstract Objective To evaluated the performance of FIB-4 score as a screening tool to detect significant liver fibrosis (F2) compared to transient elastography (TE) among chronic transfusion-dependent beta-thalassemia (TDT) patients, in a resource-poor setting. Design A cross-sectional study Setting Adolescent and Adult Thalassaemia Care Center (University Medical Unit) Kiribathgoda Sri Lanka. Participants 45 TDT patients who have undergone more than 100 blood transfusions with elevated serum ferritin more than 2000ng/mL were selected for the study. Patients who were serologically positive for hepatitis C antibody were excluded. Outcome measures TE and FIB-4 score were estimated at the time of recruitment in all participants. Pre-defined cut-off values for F2 extracted from previous studies for TE and FIB-4 score were compared. A new cut-off value for FIB-4 score was estimated using ROC curve analysis to improve the sensitivity for F2 prediction. Results Of the selected 45 TDT patients 22(49%) were males. FIB-4 score showed a significant linear correlation with TE (r= 0.52 p< 0.0003). The FIB-4 score was improbable to lead to a false classification of TDT patients to have F2 when the FIB-4 cut-off value was 1.3. On the other hand it had a very low diagnostic yield in missing almost all (except one) of those who had F2. Using a much-lowered cut-off point of 0.32 for FIB-4 we improved the pick-up rate of F2 to 72%. Conclusions Regardless of the cut-off point FIB-4 score cannot be used as a good screening tool to pick-up F2 in patients with TDT irrespective of their splenectomy status. On the contrary at 1.3 cut off value though FIB-4 is a very poor detector for F2 fibrosis it will not erroneously diagnose F2 fibrosis in those who do not have it.


2022 ◽  
Author(s):  
Silvia Giagio ◽  
Andrea Turolla ◽  
Tiziano Innocenti ◽  
Stefano Salvioli ◽  
Giulia Gava ◽  
...  

Background/aim: Several epidemiological studies have found a high prevalence of Pelvic Floor Dysfunction (PFD) among female athletes. However, according to several authors, these data could even be underestimated, both in research and clinical practice. Screening for potential PFD is often delayed and risk factors are not often evaluated. As a consequence, withdrawal from sport, negative influence on performance, worsening symptoms and unrecognized diagnosis may occur. The aim of our research is to develop a screening tool for pelvic floor dysfunction in female athletes useful for clinicians (musculoskeletal/sport physiotherapists, sports medicine physicians, team physicians) to guide referral to a PFD expert (e.g. pelvic floor/women's health physiotherapist, gynecologist, uro-gynecologist, urologist). Methods: A 2-round modified Delphi study will be conducted to ascertain expert opinion on which combination of variables and risk factors should be included in the screening tool. Conclusion: The implementation of the present screening tool into clinical practice may facilitate the referral to a PFD expert for further assessment of the pelvic floor and therefore, to identify potential dysfunction and, eventually, the related treatment pathway.


2022 ◽  
Vol 5 (4) ◽  
pp. e202101203
Author(s):  
Yasunori Park ◽  
Rachael A West ◽  
Pranujan Pathmendra ◽  
Bertrand Favier ◽  
Thomas Stoeger ◽  
...  

Nucleotide sequence reagents underpin molecular techniques that have been applied across hundreds of thousands of publications. We have previously reported wrongly identified nucleotide sequence reagents in human research publications and described a semi-automated screening tool Seek & Blastn to fact-check their claimed status. We applied Seek & Blastn to screen >11,700 publications across five literature corpora, including all original publications in Gene from 2007 to 2018 and all original open-access publications in Oncology Reports from 2014 to 2018. After manually checking Seek & Blastn outputs for >3,400 human research articles, we identified 712 articles across 78 journals that described at least one wrongly identified nucleotide sequence. Verifying the claimed identities of >13,700 sequences highlighted 1,535 wrongly identified sequences, most of which were claimed targeting reagents for the analysis of 365 human protein-coding genes and 120 non-coding RNAs. The 712 problematic articles have received >17,000 citations, including citations by human clinical trials. Given our estimate that approximately one-quarter of problematic articles may misinform the future development of human therapies, urgent measures are required to address unreliable gene research articles.


Author(s):  
Reza Fathi-Fazl ◽  
ZHEN CAI ◽  
W. Leonardo Cortés-Puentes ◽  
Farrokh Fazileh

The National Research Council Canada (NRC) recently developed a semi-quantitative seismic risk screening tool (SQST) for existing buildings in Canada. The SQST aims to supersede the Manual for Screening of Buildings for Seismic Investigation developed by NRC in the early 1990s. The SQST consists of three key components: (1) a structural scoring system that quantitatively assesses the structural seismic risk based on probability of collapse; (2) a non-structural component scoring system that qualitatively assesses the seismic risk of non-structural components based on seismic demand; and (3) a ranking procedure that prioritizes potentially hazardous buildings for seismic evaluations and possible upgrading. The SQST intends to inexpensively identify and exempt buildings with acceptable life safety risk and optimize the allocation of resources to assess the seismic risk of portfolios of buildings. Seismic screening with the SQST can be completed with either paper-based screening forms or a web-based application. The applicability of the SQST is demonstrated by conducting a pilot study for 33 existing buildings across Canada.


2022 ◽  
Vol 0 (0) ◽  
Author(s):  
Christine Kettle ◽  
Lauren McKay ◽  
Anthony M. Cianciolo ◽  
Stephen M. Kareha ◽  
Cara E. Ruggeri

Abstract Context Movement of the human body is essential for the interaction of an individual within their environment and contributes to both physical and emotional quality of life. Movement system disorders (MSDs) are kinesiopathologic conditions that result from either altered movement patterns, trauma, or pathology. A screening tool may facilitate earlier diagnosis and treatment of acute MSDs. This tool could prevent progression to chronic conditions, leading to better patient outcomes and quality of life. Objectives Our study evaluated whether a screening tool would be able to accurately screen individuals for MSDs, explore comorbidities that may predict the prevalence of MSDs, and identify why people do not discuss these problems with their primary care provider (PCP). Methods A multisite, observational study in a primary care setting. Data were analyzed to determine the psychometric properties of the screening question. Logistic regression was performed to explore the relationship of comorbidities with MSDs. Thematic analysis was performed to explore why patients do not discuss these issues with their PCP. Results The point prevalence of MSDs was determined to be 78%. The sensitivity of the screening question was determined to be good (70%). Arthritis, obesity, sleep disorders, and gastroesophageal reflux disease (GERD) were significant predictors for an MSD. Thematic analysis regarding why patients do not discuss the MSD with their physician revealed: (1) the perceived lack of importance of the problem; (2) the lack of access to healthcare, and (3) the acuity of the problem. Conclusions Screening for an MSD and associated comorbidities could prevent the transition of acute conditions to chronic conditions. If PCPs can identify predictors and factors associated with an MSD, they may be able to screen for MSDs more effectively. Earlier identification of MSDs may facilitate earlier treatment and prevent costs associated with resulting chronic disorders and persistent pain and disability.


Sign in / Sign up

Export Citation Format

Share Document